TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05643066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg esketamine
Description: Esketamine 0.1 mg/kg was intravenously injected first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg esketamine
Description: Esketamine 0.2 mg/kg was intravenously injected first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline was intravenously injected first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
Study: NCT04872686

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral and nasal spray by distilled water to control group
Description: Placebo comparator: Distilled Water Oral and Nasal spray will be provided by Distilled water to control group
Study: NCT05831787

Intervention type: OTHER
Intervention: Patient Reported Outcomes
Description: Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
Study: NCT05643066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
Study: NCT05003739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip arthroplasty with Logica Mirror femoral stem
Description: Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
Study: NCT04757675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.3
Description: 0.3 μg/kg intravenous injection s-ketamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.5
Description: 0.5 μg/kg intravenous injection s-ketamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 2
Description: 2 μg/kg intranasal s-ketamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 1+Dexmedetomidine 1
Description: 1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
Study: NCT05043077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%
Description: 1 drop (6.5 μL) for 3 doses with 5-minute intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%
Description: 1 drop (28-34 μL) for 3 doses with 5-minute intervals
Study: NCT05377320

Intervention type: OTHER
Intervention: Clinical Decision Aid
Description: The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.

Intervention type: OTHER
Intervention: Standard Care
Description: Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
Study: NCT04757675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.5 +Dexmedetomidine 2
Description: 0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
Study: NCT05570175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application RA joint protection and activity self-management program
Description: The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
Study: NCT05596110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENS and KT
Description: TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: TENS and sham taping
Description: TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: KT and sham TENS
Description: KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham TENS and sham taping
Description: Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
Study: NCT04868695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
Description: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
Description: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
Description: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
Study: NCT05904769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFELEAF Smartwatch
Description: Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFELEAF Smartwatch
Description: Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
Study: NCT06425172

Intervention type: DEVICE
Intervention: Cranial Remolding Orthosis
Description: A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
Study: NCT06275646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP layer
Description: platelet rich plasma layer was applied in addition to dartos flap

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dartos flap
Description: dartos flap alone was used

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dartos flap
Description: dartos flap alone was used
Study: NCT06039878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bonding-Evoked Oxytocin
Description: Mother participates in bonding activity with infant at ages 1, 3, and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Relieving Effects of Sucrose
Description: Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hedonic Response to Sucrose
Description: Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Typical versus Challenging Feeding-Social
Description: Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Compensation-Social
Description: Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)
Description: When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
Study: NCT05519839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: qNIV Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: qNIV Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: qNIV Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIC Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIC Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIC Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIC Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70
Study: NCT05090722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureWick System
Description: The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
Study: NCT06046313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine for Injection
Description: 6mg/m2, ivgtt qd d1-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VENCLYXTO
Description: 100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
Study: NCT05228613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 inactivated vaccine
Description: active control manufactured by Sinovac Life Sciences Co.Ltd
Study: NCT06205511

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral HPV Sample
Description: The study participant will be asked to provide an oral swish and spit sample. This sample collection will follow the procedure published by (Herrero et al 2013). The specimen is collected by a 15-second rinse followed by a 15-second gargle using 15 ml of an alcohol-based mouth wash such as a commercially available product, Scope. The 15-ml samples will then be stored at -20 and then shipped on dry ice to Dr. Anna Giuliano's laboratory in Tampa Florida for HPV testing. At present Dr. Giuliano's laboratory is using the DDL SPF10 LiPA assay for sample analysis. An oral exam will be performed for each patient by the Vivent Dentist within 30 days of the collection of the HPV sample. If a referral is needed to an oral surgeon or Ears, Nose, and Throat specialist this will be done within 60 days of the dentist visit. The HPV results will not be shared with the participants as these are research study results and not part of standard of care.
Study: NCT05403047

Intervention type: DRUG
Group type: OTHER
Intervention: Fumarate, Tenofovir Disoproxil
Description: all participants receive the intervention
Study: NCT06475131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B16D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06434532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: v-Care Online Game
Description: A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case-based online discussion
Description: A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
Study: NCT04779645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: 12-Week, once weekly subcutaneous injection with 70mg REMD-477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12-Week, once weekly subcutaneous injection with placebo
Study: NCT06402500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icon Infiltrant
Description: White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioactive infiltrant
Description: White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
Study: NCT06019286

Intervention type: DIAGNOSTIC_TEST
Intervention: SCINEXA score
Description: - 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54

Intervention type: DIAGNOSTIC_TEST
Intervention: SCINEXA score
Description: - 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
Study: NCT06211803

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron-Emission Tomography Imaging
Description: Examination of radiation distribution in the patient brain and body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
Study: NCT05051852

Intervention type: OTHER
Intervention: Follow up
Description: Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
Study: NCT04509076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP iT! (plus usual PrEP care)
Description: The PrEP iT! intervention is a mobile-optimized website, with the following components:~* PrEP Adherence, PrEP Appointment, and Sexual Activity Self-Monitoring~* Tailored feedback on PrEP adherence/non-adherence~* PrEP and sexual health information tailored for YMSM~* Text message reminders for PrEP adherence and healthcare appointments~* An ask the expert feature

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual PrEP care
Description: Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
Study: NCT05228223

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular monitoring
Description: TOF monitoring

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular monitoring
Description: TOF monitoring

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular monitoring
Description: TOF monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reverse of NMB with sugammadex
Description: Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reverse of NMB with Sugammadex and neostigmin low dose
Description: Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reverse of NMB with Sugammadex and neostigmin high dose
Description: patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg
Study: NCT05908240

Intervention type: OTHER
Group type: OTHER
Intervention: Care Coordinator Model
Description: A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
Study: NCT06574282

Intervention type: DIAGNOSTIC_TEST
Intervention: Second alkaline phosphatase measurement
Description: (1-4 weeks after the 1st measurement)

Intervention type: DIAGNOSTIC_TEST
Intervention: Second alkaline phosphatase measurement
Description: (1-4 weeks after the 1st measurement)
Study: NCT05106491

Intervention type: DEVICE
Group type: OTHER
Intervention: Synchronized Cardiac Support with the icor kit
Description: Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
Study: NCT05611710

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)